Kymera Therapeutics

KYMR

Market cap $7.27B

Kymera Therapeutics shares jump after FDA grants Fast Track to KT-621 for eosinophilic asthma, spotlighting its first-in-class STAT6 degrader potential.

Kymera Therapeutics remains a "Strong Buy", driven by positive phase 1b data for KT-621 in atopic dermatitis and pipeline expansion. KT-621 achieved a mean 63% EASI reduction and 40% pruritus NRS reduction, supporting advancement into phase 2b BROADEN2 [AD] and BREADTH [asthma] trials. Both AD and asthma programs received FDA Fast Track Designation, with mid-2027 [BROADEN2] and late-2027 [BREADTH] data readouts as key milestones.

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track designation previously granted for KT-621 for moderate to severe AD WATERTOWN, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to KT-621, its first-in-class oral STAT6 degrader, for the treatment of moderate to severe eosinophilic asthma.

Kymera Therapeutics secures $45M as Gilead licenses KT-200, advancing a novel CDK2 degrader with potential in breast cancer and solid tumors.

Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621's compelling oral profile

Sold 62,013 shares of Kymera Therapeutics; estimated transaction value $4.19 million (based on mean unadjusted close for the quarter). The quarter-end position value increased by $2.41 million, reflecting both share sales and price movement.

Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that data from its KT-621 BroADen Phase 1b clinical trial in patients with atopic dermatitis will be presented in a late-breaking oral session at the American Academy of Dermatology (AAD) 2026 Annual Meeting. The meeting will be held March 27-31, 2026, in Denver, CO. Kymera will also host a booth (#3551) in the congress exhibit hall.

Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi had one line on the February 26, 2026 earnings call that deserves attention beyond the headline numbers: his company just put the first IRF5-directed therapy in human history into the clinic.